Trial · NCT05070260
Registered outcomes77
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 77
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Binary Poor Outcome on the mRS defined by a score of 4-6 (versions 0-3) | Day 90 | To show the efficacy of glenzocimab vs. placebo, on the "poor outcome" defined as a mRS score of 4-6 (vs 0-3) assessed at Day 90 |
| Secondary | Key Secondary Efficacy Endpoint - mRS | Day 90 | Binary "Favorable Outcome" on the mRS defined by a score of 0-2 (versus 3-6) |
| Secondary | Mortality | Day 90 | All cause mortality |
| Secondary | mRS | Day 90 | To assess the favorable responses defined as mRS score of 0-1 |
| Secondary | mRS | Day 90 | To assess the favorable responses defined as mRS score of 5-6 |
| Secondary | Ordinal mRS | Day 90 | To assess the shift analysis |
| Secondary | Utility Weighted mRS | Day 90 | To assess the utility weighted mRS (UW-mRS) |
| Secondary | All cause mortality | 72 hours | To assess all cause mortality |
| Secondary | ICHs | 72 hours | Symptomatic and non-symptomatic ICHs |
| Secondary | Neurological Status Change as assessed by NIHSS value compared to pre-IVT value | 24 hours | Response defined by a relative decrease (%) in NIHSS value at 24 hours compared to pre-IVT value higher than 30%. Relative change (%) in NIHSS value at 24 hrs compared to pre-IVT value |
| Secondary | Recanalization rate | Day 90 | To assess recanalization in patients undergoing thrombectomy by eTICI score |
| Secondary | Cerebral tissue reperfusion | Day 90 | To assess Cerebral tissue reperfusion |
| Secondary | Infarct volume progression and hemorrhagic transformation | 24 hrs | To assess the impact on follow up imaging (follow up infarct volume, infarct growth and volume of hemorrhagic transformation) |
| Secondary | Measure of Quality of Life by EuroQol-5 Dimension-5 Level (EQ-5D-5L) | Day 90 | Quality of Life as assessed by the EuroQol-5 Dimension-5 Level. A Quality-of-Life Scale (EQ-5D-5L) |
| Secondary | Incidence of Deaths | Day 90 | Deaths within the first 24 hours and over the whole study period until Day 90 (Kaplan-Meier curve) |
| Secondary | Incidence of Symptomatic intracranial hemorrhages | 24 hours | Symptomatic intracranial hemorrhages, defined by both anatomical imaging (according to Heidelberg's classification) at the time of its occurrence associated with an increase in NIHSS score by 4 points or greater, or death that is not explained otherwise (according to ECASS III study definition (14)) |
| Secondary | Incidence of Non-symptomatic hemorrhages | 24 hours | Non-symptomatic hemorrhages, seen on 24-hours plain CT-Scan, not present at baseline assessment, once other diagnoses are excluded |
| Secondary | Incidence of Adverse Events, SAEs, bleeding-related events, and Treatment-Emergent Adverse Events (TEAEs) | Day 90 | Incidence, nature and severity of Adverse Events, SAEs, bleeding-related events, and Treatment-Emergent Adverse Events (TEAEs) |
| Secondary | Change in vital signs (Blood Pressure) at any visit or discharge as compared to Baseline | 24 hours | Blood Pressure will be assessed every 30 minutes during the 6 hours (infusion) then every 3 hours up to 24 hours. |
| Secondary | Change in vital signs (Heart Rate) at any visit or discharge as compared to Baseline | 24 hours | Heart Rate will be assessed every 30 minutes during the 6 hours (infusion) then every 3 hours up to 24 hours |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05070260/registered